Nathan’s Story: VCP Disease and the need for a Rare Disease Advisory Council in Georgia

Since I was a freshman at Georgia Tech, I have had a clock ticking in my head.  Since my mother presented symptoms of the VCP gene mutation, I had grown up knowing that a rare disease existed in my family and that there was a 50% chance that I might get it as an adult in my 30’s to 40’s. My mother and aunt are both deceased from the disease, and I have two uncles (four out of six siblings) that possess the VCP gene mutation that was passed down from their mother.  Symptoms include muscle wasting, Paget’s disease of bone, frontotemporal dementia, ALS and Parkinson’s.  A patient can get any combination of symptoms and the disease is fatal.  For ten years, my mother could not walk, feed herself, bathe herself or go to the bathroom by herself and my dad was her primary care partner.  I know what my future holds, and my advocacy work is for my three boys.

I jumped at every career opportunity to advance as quickly as possible.  Some might even say I was reckless.  I quit a six-figure job and moved my wife and two sons at the time to Boston to attend grad school at MIT as I knew I might not get another shot.  My oldest son lived in six states by the time he was nine and I did everything I could do to advance professionally in the event that I was “lucky” enough to have the gene mutation.

In my late 30’s, after feeling weakness in my muscles and receiving my positive gene mutation diagnosis from a researcher in California, I visited the Emory neuromuscular center to request a nuclear bone scan.  There are no treatments for my disease except for Paget’s disease of bone, if detected early enough.  During that first appointment, the doctor looked at me and said that he had never heard of my disease and that it might all be in my head.  My wife and I spent the next 45 minutes educating him about what to expect with a VCP gene mutation to not much success.  It wasn’t until I visited the Emory ALS Clinic that I found a doctor familiar with my genetic mutation.  I am his only patient with my genetic mutation. In rare diseases, access to specialty and timely medical care is crucial and can save lives and the unnecessary costs. Because there may be only a few experts in the world, many patients do not receive the care that they need.

After leading multiple businesses, I am now on full disability as we were “blessed” that I made some wise financial decisions to protect my family. I am still somewhat independent now, but my disease is progressive so I will continue to lose strength, energy, and the ability to walk. My wife and children are having to take a larger share of things l feel I should do, like mow the lawn, clean the gutters, and get things from the attic. I wish I could still do dad things like teach my boys to play basketball or take them camping. I am blessed with a wonderful family, but my rare disease is a burden to them. Rare disease affects everyone in the family. One in 10 people have a rare disease, 50% are pediatric diseases and only 5% of rare diseases have a cure. Rare disease affects many families in Georgia.

Others are not so “blessed” as I have been, and it is vital that we protect and advocate for those affected by rare disease.  My wife and I started a rare disease non-profit, Cure VCP Disease , in 2018, headquartered in Americus, Georgia, in order to help make life better for other rare disease families. We have funded research, facilitated scientific collaborations, and established a supportive patient community.

There are over 7,000 rare diseases and rare disease is complex.  I’ve learned how complex it is only because I am an affected patient.  HB 918, which advocates for the creation of a Rare Disease Advisory Council in Georgia will be one voice that can aid legislators, policy makers and the general Georgia population, in making prudent decisions to support and help rare disease patients and care partners in Georgia.  Finding a cure and treatment for rare disease is only half the battle. How will it be administered and most importantly, how will it be paid for?  Those are only a few of the important issues that the Rare Disease Advisory Council can help advise the people and representatives of Georgia.

March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.
March 24, 2026
A new national outlook on the life sciences real estate market is reinforcing what many in Georgia’s ecosystem have been building toward: a more disciplined, workforce-driven, and manufacturing-focused future for the industry. CBRE’s 2026 U.S. Life Sciences Market Outlook points to a sector in transition—moving away from rapid, speculative expansion toward a more measured phase defined by targeted growth, capital efficiency, and long-term sustainability. For Georgia, these trends are not just informative—they are validating. A Market Reset Creates Opportunity After several years of rapid expansion in major coastal markets, the national lab space market is recalibrating. Construction has slowed significantly, and vacancy rates—while still elevated—are stabilizing. This shift favors emerging markets like Georgia that have taken a more measured approach to growth. Rather than contending with oversupply, Georgia is well-positioned to scale intentionally—aligning infrastructure, workforce, and industry demand in a way that supports long-term success. Manufacturing and Scale-Up Are Driving Growth One of the clearest signals from the CBRE report is the increasing role of large pharmaceutical and biomanufacturing investments in driving demand. This aligns directly with Georgia’s recent momentum. From major facility expansions to increased interest in onshoring and domestic production, the Southeast—and Georgia in particular—is becoming a destination for advanced manufacturing in the life sciences. The Georgia Life Sciences Roadmap has consistently emphasized this opportunity: Strengthening biomanufacturing capacity Building workforce pipelines to support production scale Positioning Georgia as a hub for both innovation and commercialization Workforce as the Differentiator As capital becomes more selective and companies prioritize execution, talent—not space—is emerging as the defining constraint. Georgia’s investments in workforce development, including partnerships with the Technical College System of Georgia and the Georgia Bioscience Training Center, position the state to meet this moment. Through coordinated efforts across education, industry, and government, Georgia is building the kind of workforce infrastructure that enables companies to not only locate here—but to grow here. A Converging Ecosystem Another key trend highlighted in the report is the convergence of life sciences with adjacent sectors such as digital health, robotics, and advanced technologies. This is an area where Atlanta stands out. With strengths in medtech, health IT, and data-driven healthcare solutions, the region offers a broader definition of “life sciences”—one that reflects where the industry is headed, not where it has been. Looking Ahead The national life sciences sector is entering a new phase—one that rewards strategic alignment, ecosystem coordination, and long-term investment. Georgia is not starting from scratch in this environment. It has been building toward it. The Georgia Life Sciences Roadmap anticipated many of these shifts, prioritizing: Workforce development Manufacturing and scale-up capacity Industry-academic collaboration Capital and commercialization pathways As national trends continue to evolve, Georgia’s focus on disciplined, intentional growth positions the state—and the broader Southeast—as a compelling partner in the next chapter of the life sciences industry.  Read report - CBRE Chapter 9, Life Sciences - U.S. Real Estate Market Outlook 2026 https://www.cbre.com/insights/books/us-real-estate-market-outlook-2026/life-sciences
March 24, 2026
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta
MORE POSTS